Ribavirin
Ribavirin is a guanine derivative approved for treating Human coronavirus (HCV) and respiratory syncytial virus (RSV), evaluated in patients with SARS and MERS, but it has side effects, such as anaemia might prove severe at high doses [12] and whether it could offer sufficient potency against 2019-nCoV is uncertain [15]. Ribavirin, in high concentrations such as (Half- Effective Concentration (EC50) = 109.50 μM, Half- Concentration (CC50) > 400 μM, Selectivity Index (SI) > 3.65) was needed to minimize viral infection [10] and, according to preliminary results, may prove to be resistance to COVID-19.